Bristol-Myers Squibb | BMY - Gross Profit On Sales


Bristol-Myers Squibb reported $8.41B in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Abbott USD 6.65B 787M Jun/2026
ALKERMES USD 331.33M 7M Mar/2026
Amgen USD 6.89B 415M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
Biogen USD 1.82B 169.5M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Coherus Biosciences USD 8.7M 853K Dec/2025
Drreddys Laboratories INR 43.04B 3.77B Mar/2026
Eli Lilly USD 15.92B 1.33B Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
J&J USD 18.55B 1.31B Jun/2026
Medtronic USD 6.01B 595M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Novartis USD 10.07B 184M Mar/2026
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Perrigo USD 325.5M 36.7M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Phibro Animal Health USD 133.5M 12.6M Dec/2025
Prestige Brands USD 157.37M 5.79M Dec/2025
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Sanofi EUR 8.11B 343M Mar/2026
United Therapeutics USD 315.5M 286.6M Dec/2025
Zoetis USD 1.62B 20M Mar/2026